Aquestive Therapeutics, Inc.
AQST
$5.39
$0.316.10%
NASDAQ
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | -4.34% | 11.00% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -4.34% | 11.00% | |||
| Cost of Revenue | 15.80% | -40.56% | |||
| Gross Profit | -10.70% | 52.90% | |||
| SG&A Expenses | 28.11% | -66.56% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 18.19% | -55.44% | |||
| Operating Income | -95.60% | 85.42% | |||
| Income Before Tax | -183.78% | 74.71% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -183.78% | 74.71% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -183.78% | 74.71% | |||
| EBIT | -95.60% | 85.42% | |||
| EBITDA | -97.68% | 85.74% | |||
| EPS Basic | -178.39% | 74.85% | |||
| Normalized Basic EPS | -36.01% | 74.83% | |||
| EPS Diluted | -178.39% | 74.85% | |||
| Normalized Diluted EPS | -36.01% | 74.83% | |||
| Average Basic Shares Outstanding | 1.94% | 0.53% | |||
| Average Diluted Shares Outstanding | 1.94% | 0.53% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||